Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

QIAGEN N.V. QGEN

Healthcare — Diagnostics & Research

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.73%

Capital & Financial Ratios

Market Cap
9,150.00
Revenue
2,100.36
Net Income
409.32
Free Cash Flow
440.60
Net Debt
850.12
Current Ratio
2.85
Debt/Equity
0.49
P/E ratio
22.20
P/S ratio
4.26
P/B ratio
2.66
Past 5Y EPS Growth
12.66%
This Y EPS Growth
1.92%
Next Y EPS Growth
7.65%
Next 5Y EPS Growth
6.27%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 0.14
—
2025 0.20
—
—
2024 1.37
—
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1,057.78 1,152.99 1,098.92 793.50
Receivables 381.88 349.28 402.61 389.85
Inventory 398.39 279.26 301.89 311.36
Other — — — —
2,147.56 1,959.85 1,995.07 1,656.63
2023 2024 2025 Q'26
Payables 84.16 83.27 72.66 79.08
ST’ Debt 587.97 551.88 — 16.52
Other — — — —
1,079.29 1,042.03 512.14 581.45
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 492.32 535.04 — —
—
’25 483.46 533.54 532.58 540.42
2,090.00
’24 458.80 496.35 501.87 521.20
1,978.21
’23 485.40 494.86 475.89 509.16
1,965.31
’22 628.39 515.51 499.63 497.98
2,141.52
’21 567.21 567.31 534.75 582.40
2,251.66
’20 372.10 443.25 483.76 571.23
1,870.35
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 100.63 200.69 — —
—
’25 139.74 161.44 165.02 188.13
654.33
’24 133.08 166.62 182.35 191.51
673.55
’23 71.93 111.48 124.68 151.37
459.46
’22 207.41 171.95 211.58 124.32
715.26
’21 128.63 156.40 155.52 198.46
639.00
’20 15.91 134.68 37.50 269.71
457.81
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 52.15 157.32 — —
—
’25 95.48 120.60 114.57 116.55
447.20
’24 94.72 127.71 138.03 141.85
502.31
’23 33.52 80.35 83.64 99.15
296.65
’22 169.00 134.34 184.86 77.73
565.93
’21 73.67 110.10 104.24 144.46
432.47
’20 (12.01) 12.73 (50.22) 203.07
153.57
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.33 0.50 — —
—
’25 0.43 0.46 0.63 0.49
1.94
’24 0.39 (0.90) 0.48 0.41
0.39
’23 0.41 0.39 0.38 0.45
1.60
’22 0.75 0.47 0.40 0.44
2.05
’21 0.63 0.58 0.64 0.63
2.47
’20 0.19 0.42 0.08 1.02
1.71

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 41.67 35.85 39.03 37.63 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.88 52.82 47.44 51.88 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,178 5,967 5,765 5,654 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.35 0.33 0.34 0.37 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,141.52 1,965.31 1,978.21 2,090.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64.65% 62.77% 48.90% 62.18% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 512.60 429.81 121.15 490.27 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.94% 21.87% 6.12% 23.46% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 423.21 341.30 83.59 424.88 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 242.10 235.50 221.70 197.11 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.19 9.07 8.89 9.62 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.05 1.60 0.39 1.94 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.40 2.12 3.03 3.01 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.71) (0.75) (0.77) (0.95) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.69 1.37 2.26 2.06 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.49 17.57 16.02 17.39 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 210.19 216.74 222.62 217.22 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.09 27.50 117.80 22.30 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.06 4.97 5.01 4.67 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.12 2.56 2.78 2.59 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.26 5.20 5.13 5.18 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.92 34.44 20.21 24.20 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 715.26 459.46 673.55 654.33 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (149.34) (162.80) (171.24) (207.13) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 565.93 296.65 502.31 447.20 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,419.43 1,068.27 917.82 1,482.94 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,861.45 1,509.79 1,391.55 1,654.43 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 443.18 452.01 238.56 555.51 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,466.61 3,807.76 3,567.34 3,778.15 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.81% 5.50% 1.42% 7.10% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.50% 6.01% 1.60% 6.72% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.90% 9.38% 2.27% 11.57% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

QIAGEN N.V. (QGEN) rode a COVID-19 revenue surge from $1.34 billion in 2016 to a $2.25 billion peak in 2021, but post-pandemic reality has stalled growth at a projected 0.4% for 2024 ($1.98 billion), with revenue per employee down 12% to $329,000. Gross margins have cratered to 48.9% in 2024 from mid-60% pre-2021, dragging EPS 84% lower to $0.39 and ROE to 2.3%, amid input cost inflation and PCR market commoditization. Despite a solid balance sheet with net debt at $239 million and positive free cash flow ($502 million in 2024), zero insider activity over 12 months signals caution in a competitive genomics landscape dominated by Illumina and Thermo Fisher.

Analyst forecasts promise rebound—revenue up 6% annually to $2.35 billion by 2027, EPS to $2.36, and margins recovering to 62%—implying 8% mean upside to price targets. Yet valuations strain credulity: 118x trailing PE on depressed earnings, PS ratios at 4.5-5x despite stagnation, and heroic assumptions of 23.5% EBT margin revival. Stock resilience, trading just 17% off 2021 highs amid 12% revenue decline, hints at multiple expansion over fundamentals, exposing risks from market saturation, Asia exposure, and macro shocks.

This disconnect—priced for perfection yet masking eroding moats—positions QGEN as a potential value trap if 2025 disappoints. Read the full analysis for quantitative deep dives into cash flows, acquisitions’ impact, and probabilistic scenarios.

Read full commentary →

QIAGEN N.V. (QGEN) Latest News

News by impact score

Fine-tune

17 Sep

4 investorshub.advfn.com, 8:32 AM
Qiagen shares rose 4% on reports of private equity takeover interest. Potential private equity takeover signals major ownership and strategic shift for Qiagen.

3 , 1:20 AM
QIAGEN launches QIAsymphony Connect after Q2 outperformance. Product rollout after strong Q2 results indicates moderate effects on operations and market position.

5 Sep

4 , 3:06 PM
Qiagen launches new automation platform, undergoes CEO transition and beats Q2 expectations, shaping QGEN investor outlook. Automation platform rollout, CEO change and Q2 beat mark major operational and strategic shifts for Qiagen.

3 , 5:06 PM
Qiagen beat Q2 estimates and reaffirmed outlook, with analysis questioning if the stock remains below fair value. Q2 earnings beat and reaffirmed outlook moderately affects financial performance and investor sentiment.

28 Aug

4 , 4:33 PM
Qiagen received FDA clearance opening a new diagnostics market with potential to lift its stock performance. FDA clearance grants access to new diagnostics market that can drive major revenue growth and shift competitive position.

27 Aug

3 , 4:05 PM
QIAGEN launches QIAsymphony Connect for automated clinical nucleic acid extraction. New automated extraction system launch supports product innovation but represents incremental rather than transformative advancement.

25 Aug

3 www.medtechdive.com, 6:00 AM
Qiagen names new CEO. CEO appointment may influence strategy and sentiment without guaranteed fundamental change.

24 Aug

4 , 10:26 AM
Qiagen appoints Jonathan Pratt as CEO amid ongoing takeover talks. CEO appointment during takeover discussions signals major strategic shifts with potential to alter company trajectory and investor sentiment.

4 , 9:47 AM
QIAGEN N.V. appoints Jonathan M. Pratt as Chief Executive Officer. New CEO appointment represents major leadership shift with potential to alter strategy and investor sentiment.

14 Aug

4 , 5:17 AM
Qiagen beat Q2 expectations and obtained FDA clearance, leaving the stock 4% undervalued. Q2 earnings beat plus FDA clearance strengthen financial results and regulatory approvals.

13 Aug

4 , 8:10 AM
Qiagen receives FDA clearance for QIAstat-Dx Bloodstream Panel, potentially shifting its syndromic testing position. FDA clearance of QIAstat-Dx Bloodstream Panel marks major regulatory approval that can expand Qiagen diagnostics revenue and competitive edge.

3 , 2:50 PM
Qiagen (QGEN) exceeded its guidance but experienced margin slippage. Guidance beat offset by margin decline points to mixed operational results likely affecting short-term investor views on Qiagen profitability.

3 transcript www.fool.com, 2:13 AM
Qiagen (QGEN) held its Q2 2026 earnings call to discuss financial results and outlook. Earnings call provides financial metrics and guidance that may influence short-term market sentiment and operations.

10 Aug

4 , 4:05 PM
QIAGEN receives U.S. FDA clearance for its first QIAstat-Dx Bloodstream Infection Panel. FDA clearance for new diagnostic panel supports product expansion and revenue potential in QIAGEN's core molecular diagnostics business.

3 , 9:15 AM
Qiagen derives substantial revenue from international markets, with notable exposure to Europe and Asia that shapes its overall financial performance amid currency and regional demand shifts. International revenue concentration creates moderate exposure to currency swings and regional economic conditions without altering core operations.

8 Aug

3 transcript www.marketbeat.com, 10:03 PM
Qiagen Q2 earnings call highlighted revenue, adjusted EPS results, segment performance details and updated annual guidance. Q2 earnings updates deliver financial metrics and guidance that moderately influence near-term investor expectations.

6 Aug

4 app.moby.co, 8:30 AM
Qiagen N.V. released its Q2 2026 earnings call summary covering financial results and operational updates. Earnings call details typically drive significant shifts in investor sentiment and stock trajectory for QIAGEN N.V.

5 Aug

3 , 7:30 PM
Qiagen (QGEN) reported Q2 earnings with key metrics compared against analyst estimates. Q2 earnings metrics versus estimates can influence short-term stock movement and investor views on financial health.

3 , 4:05 PM
QIAGEN exceeded its Q2 2026 outlook with solid sales growth from its pillars and reaffirmed its full-year outlook. Quarterly beat with unchanged annual guidance points to moderate short-term market gains without major trajectory shifts.

29 Jul

3 , 10:00 AM
Analysts estimate Qiagen (QGEN) will report a decline in earnings, highlighting key factors for investors to monitor ahead of the release. Expected earnings decline may influence Qiagen stock performance and investor outlook.

23 Jul

3 , 4:12 AM
KKR interest in Qiagen combined with Allyntra launch returns focus to Qiagen valuation. KKR interest may create takeover speculation affecting short-term valuation but lacks confirmed deal or operational changes.

14 Jul

3 , 4:05 PM
QIAGEN expands QIAstat-Dx bloodstream infection testing menu in Europe. European menu expansion for QIAstat-Dx adds moderate product reach and revenue upside for QIAGEN.

10 Jul

4 , 8:16 PM
Takeover speculation surrounds Qiagen (QGEN) and refocuses attention on its valuation. Takeover speculation frequently triggers major valuation swings and strategic shifts for Qiagen.

9 Jul

4 , 10:12 PM
Qiagen (QGEN) stock may be 23% below fair value despite takeover interest. Takeover interest combined with clear undervaluation points to major effects on stock trajectory and strategic outcomes.

4 stocktwits.com, 1:19 PM
QIAGEN N.V. stock recorded its largest single-day gain in nearly six months after reports of takeover interest emerged, lifting investor optimism. Takeover interest signals potential ownership change and strategic shift for QIAGEN.

4 , 11:28 AM
Qiagen attracts early takeover interest from EQT, Advent, KKR. Potential acquisition interest from major private equity firms signals significant ownership and strategic shifts ahead.

15 Jun

3 , 11:16 AM
QIAGEN expands QIAcuity Gene Expression Portfolio to increase adoption of digital PCR technology. Portfolio expansion strengthens QIAGEN product innovation and competitive positioning in dPCR and gene expression markets.

3 , 1:30 AM
QIAGEN expands QIAcuity gene expression portfolio to accelerate digital PCR adoption in research and biopharma applications. Portfolio expansion strengthens digital PCR offerings and supports incremental competitive gains in core markets.

3 Jun

3 Insider Monkey, 9:51 AM
Speculation that Agilent Technologies may acquire QIAGEN N.V. coincides with Agilent shares declining in Q1. Acquisition speculation can move QIAGEN valuation and investor attention but remains unconfirmed.

29 May

4 Zacks, 9:16 AM
QIAGEN N.V. cut its 2026 outlook and missed Q1 estimates, prompting questions over whether QGEN stock is still a hold. 2026 outlook cut combined with Q1 miss signals material long-term pressure on QIAGEN results and valuation.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us